GLIOTRAIN consortium members, the University of Stuttgart and YUMAB, awarded grant to establish new approaches in Targeted Drug Delivery to the Brain

GLIOTRAIN investigators Professor Markus Morrison and Dr Gavin Fullstone, from the University of Stuttgart, along with GLIOTRAIN industry partner YUMAB and other partners have been awarded a grant from the Federal Ministry of Education and Research (BMBF, Germany) on the theme of Targeted Drug Delivery.

Building on co-operation from within the GLIOTRAIN programme, the “BrainAim” project aims to develop new antibody-based drugs for treatment of neurodegenerative diseases including Alzheimer’s and Parkinson’s. Employing a combination of antibody engineering, computational optimisation approaches, in vitro human cell models and rodent disease models, BrainAim will balance the need for reduced off-target drug effects, better drug delivery to the brain and specific activation of drugs at disease targets thus improving patient responses whilst simultaneously reducing side-effects.